<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28129" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Long QT Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al-Akchar</surname>
            <given-names>Mohammad</given-names>
          </name>
          <aff>Southern Illinois University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddique</surname>
            <given-names>Momin S.</given-names>
          </name>
          <aff>SIU</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammad Al-Akchar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Momin Siddique declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28129.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The QT interval on an electrocardiogram (ECG) represents the duration of the ventricular action potential, and this physiologically correlates with the duration of the ventricular depolarization and repolarization. Cardiac events and fatal arrhythmias may occur when the QT interval is prolonged either congenitally or through acquired causes. This activity reviews the causes of QT prolongation and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of prolonged QT syndrome.</p></list-item><list-item><p>Evaluate&#x000a0;the ECG features of prolonged QT syndrome.</p></list-item><list-item><p>Determine&#x000a0;the treatment and management options available for prolonged QT syndrome.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and communication to advance the management of QT prolongation and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28129&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28129">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28129.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The QT interval on an electrocardiogram (ECG) represents the&#x000a0;duration&#x000a0;of the ventricular action potential,&#x000a0;and this&#x000a0;physiologically correlates with the duration of the ventricular depolarization and repolarization. Cardiac events and fatal arrhythmias may occur when the QT interval is prolonged either&#x000a0;congenitally or through acquired&#x000a0;causes.<xref ref-type="bibr" rid="article-28129.r1">[1]</xref><xref ref-type="bibr" rid="article-28129.r2">[2]</xref><xref ref-type="bibr" rid="article-28129.r3">[3]</xref></p>
      </sec>
      <sec id="article-28129.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The causes of QT interval prolongation can be divided into congenital or acquired. Congenital causes are usually a result of mutations in ion channels (potassium, calcium, or sodium) with more than 15 identified mutations. In contrast, acquired QT interval prolongation may result from electrolyte abnormalities or drugs that affect those ion channels (see <bold>Image.</bold> Prolonged QT interval).<xref ref-type="bibr" rid="article-28129.r4">[4]</xref><xref ref-type="bibr" rid="article-28129.r5">[5]</xref><xref ref-type="bibr" rid="article-28129.r6">[6]</xref></p>
      </sec>
      <sec id="article-28129.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of congenital causes, also known as&#x000a0;Long QT syndrome (LQTS), is difficult to estimate but may be expected in 1 in 2,500 to 1 in 10,000 individuals. It is more common in females and usually presents with cardiac events in childhood, adolescence, or early adulthood. There are, however, case reports of it manifesting in the fifth decade of life. Family history is positive for&#x000a0;Long QT syndrome in 40% and for sudden cardiac death in 30% of patients. Acquired causes are relatively more common&#x000a0;than congenital causes. Some studies report the prevalence of QT prolongation in as many as 30% of patients in the intensive care unit.<xref ref-type="bibr" rid="article-28129.r7">[7]</xref><xref ref-type="bibr" rid="article-28129.r8">[8]</xref></p>
      </sec>
      <sec id="article-28129.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>A QT interval duration largely depends on the duration of the ventricular action potential. This duration largely depends on the heart's closure or opening of ion channels, with the influx of positive ions (sodium, calcium) causing depolarization and the efflux of positive ions (potassium) causing repolarization. Any disturbance in these ion channels that leads to an excess of intracellular positive ions prolongs the action potential, leading to QT prolongation. The pathophysiology of congenital and acquired causes is explained below.</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Congenital: </italic>Mutation in genes coding for ion channel proteins results in their malfunction, leading to excess intracellular positivity. Though rare, this entity results in a high risk of sudden death. So far, mutations of any of 15 genes have been linked to Long QT syndrome, with KCNQ1 being the most common gene mutated and is the cause of Long QT syndrome&#x000a0;type 1.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Acquired</italic>: More commonly, prolongation of QT interval is acquired. As one can expect, disturbances of electrolytes (hypokalemia, hypocalcemia, hypomagnesemia) prolong QT. Also, certain medications affect those ion channels and lead to QT prolongation. Virtually&#x000a0;all drugs&#x000a0;that produce Long QT syndrome&#x000a0;act by blocking the outward IKr current, which is mediated by the potassium channel encoded by the KCNH2 gene.&#x000a0;Medications known to cause this include antiarrhythmic drugs such as sotalol and amiodarone, certain antibiotics such as macrolides and fluoroquinolones, antipsychotics such as haloperidol and olanzapine, and certain gastric motility agents (such as cisapride). A great resource for knowing which drugs prolong QT interval is www.crediblemeds.org.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28129.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Syncope is the most common symptom, usually experienced during exercise and high emotions (50% of the genetic variant).&#x000a0;Syncope during swimming, including immediately after diving into the water, appears relatively specific for LQT1.&#x000a0;Other presentations include near-syncope, cardiac arrest, or seizures. In 10% to 15% of individuals, death is the first sign. Also, certain types of Long QT syndrome&#x000a0;have an additional non-cardiac phenotype. For example,&#x000a0;hearing loss is present in Jervell and Lange-Nielsen syndrome.&#x000a0;Skeletal abnormalities, such as short stature and scoliosis, are present in the LQT7 type (Andersen syndrome). Also,&#x000a0;cognitive and behavioral problems and immune dysfunction may be seen in those with LQT8 type (Timothy syndrome).</p>
      </sec>
      <sec id="article-28129.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosing prolonged QT starts by measuring the QT interval on ECG. This is often done on&#x000a0;lead II or V5-6, whichever is longer. This should be done on several successive beats, of which the longest interval is chosen. If a U wave exists and is large&#x000a0;(greater than 1 mm), and fused with&#x000a0;T-wave, then this should be included in the QT measurement. On the contrary, if the U-wave is small or separate from the T-wave, then it should be excluded. The&#x000a0;maximum slope-intercept method&#x000a0;defines the end of the T wave. A helpful tip that helps identify prolonged QT intervals during the initial examination of the ECG is that a normal QT interval should be less than half the preceding RR interval.<xref ref-type="bibr" rid="article-28129.r9">[9]</xref><xref ref-type="bibr" rid="article-28129.r4">[4]</xref><xref ref-type="bibr" rid="article-28129.r10">[10]</xref></p>
        <p>Due to the variation of QT interval with heart rate (higher heart rate has shorter QT interval, lower heart rate has longer QT interval), it is important to correct the QT interval for the heart rate. This is known as QTc.&#x000a0;QTc is prolonged if it is greater than 440 ms in men or greater than 460 ms in women. A QTc greater than 500 is associated with an increased risk of torsade de pointes. While several equations exist to help correct heart rate variation, the Bazett formula (QTC = QT / &#x0221a; RR) is the most commonly used. Though the Bazett formula seems relatively accurate in heart rates between 60 to 100 beats/min, it tends to overcorrect with higher heart rates and undercorrect with lower heart rates.</p>
        <p>Once QTc is identified as prolonged, the next step in a workup is to look for&#x000a0;acquired causes. The most common cause of QT prolongation in an ICU setting is usually drug-related.&#x000a0;Serum potassium, calcium, and magnesium levels should be checked, as low serum of each can cause QT prolongation. Also, stimulating thyroid hormone (TSH) levels may be checked in patients with suspected hypothyroidism.</p>
        <p>In the absence of reversible or acquired causes of QT prolongation, Long QT syndrome is diagnosed. In those patients, obtaining an electrocardiography of the patient and family members may be very helpful. Noncardiac phenotype (as discussed above) may aid in making the diagnosis. Genetic testing of the patient and family members is the gold standard; however, this testing is limited by cost. Pharmacologic provocation&#x000a0;with epinephrine or isoproterenol is warranted in patients with a borderline presentation. The concept of this testing is that patients with Long QT syndrome&#x000a0;have an abnormal response to sympathetic stimulation. Their ECG shows the failure of the QT interval to shorten with increased heart rates, or it may even show prolongation. In patients with LQT2, there is&#x000a0;marked shortening with exercise, however, exaggerated lengthening of the QT interval as the heart rate declines during late recovery.</p>
      </sec>
      <sec id="article-28129.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The goal of management is the prevention of lethal arrhythmias such as torsade de pointes (TdP). As described earlier, the longer the QT interval, the higher the risk is for&#x000a0;torsade de pointes. A hemodynamically unstable patient should receive&#x000a0;non-synchronized electrical defibrillation. Also, the first-line treatment is magnesium sulfate, and the benefit is independent of serum magnesium level. Temporary transvenous overdrive pacing should be considered for those who do not respond to magnesium sulfate.&#x000a0;Isoproterenol and&#x000a0;Class IB antiarrhythmic drugs, such as&#x000a0;lidocaine and phenytoin, may also be used.&#x000a0;<xref ref-type="bibr" rid="article-28129.r5">[5]</xref><xref ref-type="bibr" rid="article-28129.r11">[11]</xref><xref ref-type="bibr" rid="article-28129.r12">[12]</xref><xref ref-type="bibr" rid="article-28129.r13">[13]</xref></p>
        <p>For long-term management in congenital Long QT syndrome, beta-blockers are the first line choice, and they help prevent ventricular arrhythmias by stabilizing ventricular action potential and helping block sympathetic surges associated with arrhythmias. An implantable cardioverter&#x000a0;defibrillator (ICD) is recommended in patients with Long QT syndrome&#x000a0;who were resuscitated from a cardiac arrest. It is also indicated in those who have beta-blocker-resistant symptoms or have contraindications to beta-blockers. It also may be indicated in asymptomatic individuals&#x000a0;who are suspected to be at high risk for ventricular arrhythmias.</p>
      </sec>
      <sec id="article-28129.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for long QT syndrome include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Brugada syndrome</p>
          </list-item>
          <list-item>
            <p>Cardiac death</p>
          </list-item>
          <list-item>
            <p>Coronary artery anomalies</p>
          </list-item>
          <list-item>
            <p>Drug-induced QT prolongation</p>
          </list-item>
          <list-item>
            <p>Hypertrophic cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>QT prolongation in the course of other diseases</p>
          </list-item>
          <list-item>
            <p>Seizure</p>
          </list-item>
          <list-item>
            <p>Short QT syndrome</p>
          </list-item>
          <list-item>
            <p>Sudden cardiac death</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28129.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with a prolonged QT interval may be first identified by the primary care provider, internist, or pharmacist. It is important to refer these patients to the cardiologist/cardiac surgeon ASAP as the management is complex.</p>
        <p>The goal of management is the prevention of lethal arrhythmias such as torsade de pointes (TdP). The long-term management of congenital Long QT syndrome involves beta-blockers to help prevent ventricular arrhythmias by stabilizing ventricular action potential and helping block sympathetic surges associated with arrhythmias. An implantable cardioverter&#x000a0;defibrillator (ICD) is recommended in patients with Long QT syndrome&#x000a0;who were resuscitated from a cardiac arrest.&#x000a0;</p>
        <p>The pharmacist needs to keep track of patient medications because many can cause prolonged QT syndrome. The&#x000a0;clinicians should inform the patient to follow up with the cardiologist or primary care provider and undergo regular ECGs to ensure the condition is under control. With an interprofessional healthcare team approach, QT prolongation can be prevented or treated appropriately.</p>
      </sec>
      <sec id="article-28129.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28129&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28129">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/long-qt-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28129">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28129/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28129">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28129.s12">
        <fig id="article-28129.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Prolonged QT Interval. Prolonged QT interval in a patient admitted for COPD exacerbation after use of propofol. Southern Illinois University, Department of Internal Medicine</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="QT__prolongation" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28129.s13">
        <title>References</title>
        <ref id="article-28129.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bueno-Orovio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schilling</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kirkby</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rajamohan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burrage</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tinker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harmer</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Investigating the Complex Arrhythmic Phenotype Caused by the Gain-of-Function Mutation KCNQ1-G229D.</article-title>
            <source>Front Physiol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>259</fpage>
            <pub-id pub-id-type="pmid">30967788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dehghani-Samani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madreseh-Ghahfarokhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dehghani-Samani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mutations of Voltage-Gated Ionic Channels and Risk of Severe Cardiac Arrhythmias.</article-title>
            <source>Acta Cardiol Sin</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-110</page-range>
            <pub-id pub-id-type="pmid">30930557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alahmadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vigo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jay</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Can laypeople identify a drug-induced QT interval prolongation? A psychophysical and eye-tracking experiment examining&#x000a0;the ability of nonexperts to interpret an ECG.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>404</fpage>
            <page-range>404-411</page-range>
            <pub-id pub-id-type="pmid">30848818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giudicessi</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>AAM</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Feb</month>
            <day>06</day>
            <volume>137</volume>
            <issue>6</issue>
            <fpage>619</fpage>
            <page-range>619-630</page-range>
            <pub-id pub-id-type="pmid">29431662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beach</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Celano</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sugrue</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.</article-title>
            <source>Psychosomatics</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-122</page-range>
            <pub-id pub-id-type="pmid">29275963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cohagan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brandis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Torsade de Pointes</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29083738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebrahim</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Shepard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Genotype Positive Long QT Syndrome in Patients With Coexisting Congenital Heart Disease.</article-title>
            <source>Am J Cardiol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>15</day>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-261</page-range>
            <pub-id pub-id-type="pmid">28532774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uvelin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pejakovi&#x00107;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mijatovi&#x00107;</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.</article-title>
            <source>J Anesth</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>413</fpage>
            <page-range>413-423</page-range>
            <pub-id pub-id-type="pmid">28229241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hutton</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>The importance of routine QT interval measurement in rhythm interpretation.</article-title>
            <source>Dynamics</source>
            <year>2008</year>
            <season>Fall</season>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>29</fpage>
            <page-range>29-33</page-range>
            <pub-id pub-id-type="pmid">18773713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavero</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Crumb</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance. April 11-12, 2005, Bethesda, MD, USA.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>795</fpage>
            <page-range>795-9</page-range>
            <pub-id pub-id-type="pmid">16011455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Haugaa</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Morlan</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Tarrell</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Caraballo</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and Outcome of High-Risk QT Prolongation Recorded in the Emergency Department from an Institution-Wide QT Alert System.</article-title>
            <source>J Emerg Med</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-15</page-range>
            <pub-id pub-id-type="pmid">29107482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gromova</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Torshin</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Kalacheva</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Grishina</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>[On Synergism of Potassium and Magnesium in Maintenance of Myocardial Function].</article-title>
            <source>Kardiologiia</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>73</fpage>
            <page-range>73-80</page-range>
            <pub-id pub-id-type="pmid">28294893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28129.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chouchoulis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chiladakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koutsogiannis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davlouros</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Impact of QT interval prolongation following antiarrhythmic drug therapy on left ventricular function.</article-title>
            <source>Future Cardiol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-22</page-range>
            <pub-id pub-id-type="pmid">27990843</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
